Synthesize Bio

The company's core technology is a generative genomics foundation model, named GEM-1, which uses artificial intelligence to simulate and predict the results of lab experiments with high accuracy. This model was trained on a vast amount of publicly available RNA sequencing data, which captures gene expression in healthy and diseased human cells from various lab work and clinical trials. The platform is designed to bridge the data gap in research by allowing scientists to augment their experimental data with AI-generated datasets and harmonized public data. This capability circumvents the time-consuming biological constraints of cell growth or clinical trial recruitment, reducing processes that would typically take months down to minutes.

Synthesize Bio's platform enables researchers to generate high-fidelity bulk and single-cell RNA-seq data, test hypotheses, and analyze transcriptional responses across diverse conditions before committing to wet lab experiments. Clients, primarily scientists and researchers in the biotech and pharmaceutical sectors, can access the platform through a web interface and APIs to integrate the data into their own workflows. On September 16, 2025, the company announced it had raised $10 million in funding from Madrona Venture Group to support the platform's development and commercialization.